Botulism/Future or Investigational Therapies

MedicalTherapy{{#meta: itemprop="medicalWebPageAudiences" content="patient"}}{{#meta: itemprop="medicalWebPageSpecialities" content="cardiology"}}{{#meta: itemprop="medicalWebPageInfoTypes" content="symptoms,diagnosis,treatment,causes,prognosis,complications"}}

Overview

Botulism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Botulism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Botulism/Future or Investigational Therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Botulism/Future or Investigational Therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Botulism/Future or Investigational Therapies
CDC on Botulism/Future or Investigational Therapies
Botulism/Future or Investigational Therapies in the news
Blogs on Botulism/Future or Investigational Therapies
Directions to Hospitals Treating Botulism
Risk calculators and risk factors for Botulism/Future or Investigational Therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Michael Maddaleni, B.S., Hafiz M. Ahmed, M.D.[2]

Overview

Antitoxin and supportive care remain the established treatment approach for symptomatic botulism. The CDC 2021 guideline discusses several proposed adjunctive treatments but identifies no established clinical benefit from these alternatives. They should not replace or delay antitoxin administration or respiratory support. See Botulism medical therapy for standard treatment.

Investigational and Adjunctive Therapies

Agents intended to enhance acetylcholine release

Guanidine and 3,4-diaminopyridine have been used in attempts to increase acetylcholine release and improve neuromuscular transmission. The CDC 2021 guideline describes apparently transient effects in published reports, without establishing a clear clinical benefit.

Plasma exchange

Plasma exchange has been used in patients with botulism, but the CDC 2021 guideline reports no clear benefit.

References

Related Pages

• Adverse Outcomes:
• Contraindications:
• Duplicate Therapies:
• Indications: {{:}}
• Prevents:
• Treats:Botulism